The Takeover! Eli Lilly Ascends the Pharmaceutical Throne and Leaves Novo Nordisk in the Dust!

Eli Lilly (LLY) is no longer just a pharmaceutical company; it is an unstoppable growth machine. While the competition stumbles, the company from Indianapolis delivers numbers that exceed even the boldest dreams of Wall Street. In the 4th quarter, revenue exploded by 43% to $19.3 billion. However, the real sensation is the profit. An EPS jump of over 50% shows that Lilly is not only growing but is also ruthlessly profitable. The key to this triumph is a rapidly growing business in procurement products, which is ringing the cash registers like never...